Skip to main content

Uromonitor Bladder Cancer Recurrence Test

Uromonitor has launched its genetic test for detecting the recurrence of bladder cancer. Also called Uromonitor, the urine-based test detects trace amounts of FGFR3 and Tert promoter mutations, which are associated with early stages of bladder cancer. Portugal's Institute of Molecular Pathology and Immunology of the University of Porto, and the Institute for Research and Innovation in Health developed the test, which is CE marked.